4-(苯乙基氨基)吡啶 | 15935-79-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(苯乙基氨基)吡啶
• 英文名称: 4-(phenethylamino)pyridine
• 英文别名: 4-Phenethylamino-pyridin；phenethyl-pyridin-4-yl-amine；Phenaethyl-[4]pyridyl-amin；N-(2-Phenylethyl)-4-pyridinamine；Pyridine, 4-(phenethylamino)-；N-(2-phenylethyl)pyridin-4-amine
• CAS: 15935-79-2
• 化学式: C₁₃H₁₄N₂
• 分子量: 198.268
• InChiKey: SYEYBZWRMMNJAY-UHFFFAOYSA-N

物化性质

• 沸点：
  377.3±25.0 °C(Predicted)
• 密度：
  1.105±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  、 4-(苯乙基氨基)吡啶 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 作用下， 生成 2-(5-bromo-2-fluorophenyl)-4-[(phenethyl)(4-pyridyl)amino]-pteridine
  参考文献：
  名称：

  Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

  摘要：

  Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-2-fluoro-phenyl)pteridin-4-ylamino]-N-[3-(2-oxopyrrolidin-1-yl)propyl]nicotinamide 36 with a replicon EC50 of 64 nM, associated with a selective kinase inhibitory profile for human JNK kinases 2 and 3 as well as VEGFR-1, 2, and 3 kinases. Moreover, 36 showed an advantageous PK profile in mice. Experiments performed using different replicon constructs suggest that this series of kinase inhibitors might mediate their effect through the HCV non-structural protein 5A (NS5A). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.046
• 作为产物：
  描述：

  4-氨基吡啶 以 乙醚 、 甲苯 为溶剂， 反应 20.0h， 生成 4-(苯乙基氨基)吡啶
  参考文献：
  名称：

  Katritzky, Alan R.; Rachwal, Stanislaw; Wu, Jing, Canadian Journal of Chemistry, 1990, vol. 68, # 3, p. 456 - 463

  摘要：

  DOI：

文献信息

• N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or
  申请人：DowElanco

  公开号：US05399564A1

  公开（公告）日：1995-03-21

  N-(4-Pyridyl or 4-quinolinyl) arylacetamides, for example N-((3-chloro-2-ethyl)-4-pyridyl)(4-(4-chlorophenoxy) phenyl)-acetamide, and 4-(aralkyoxy or aralkylamino)pyridines, for example 4-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethoxy]pyridine, are active against nematodes, insects, mites, and plant pathogens.

  N-(4-吡啶基或4-喹啉基)芳基乙酰胺，例如N-((3-氯-2-乙基)-4-吡啶基)(4-(4-氯苯氧基)苯基)-乙酰胺，以及4-(芳基氧基或芳基氨基)吡啶类化合物，例如4-[2-[4-(2,2,2-三氟乙氧基)苯基]乙氧基]吡啶，对线虫、昆虫、螨虫和植物病原体具有活性。
• N-(4-pyridyl) (substituted phenyl) acetamide pesticides
  申请人：DowElanco

  公开号：US05597836A1

  公开（公告）日：1997-01-28

  N-(4-Pyridyl) arylacetamides, for example N-((3-chloro-2-ethyl)-4-pyridyl)(4-(4-chlorophenoxy)phenyl)-acetamide, and 4-(aralkyoxy or aralkylamino)pyridines, for example 4-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethoxy]pyridine, are active against nematodes, insects, mites, and plant pathogens.

  N-(4-吡啶基)芳基乙酰胺，例如N-((3-氯-2-乙基)-4-吡啶基)(4-(4-氯苯氧)苯基)-乙酰胺，以及4-(芳基氧基或芳基基氨基)吡啶，例如4-[2-[4-(2,2,2-三氟乙氧)苯基]乙氧]吡啶，对线虫、昆虫、螨和植物病原体具有活性。
• Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：US20140094468A1

  公开（公告）日：2014-04-03

  The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

  本发明涉及使用蚀刻酸类作为HCV复制抑制剂，以及它们在旨在治疗或对抗HCV感染的药物组合物中的使用。此外，本发明涉及化合物本身及其作为药物的使用。本发明还涉及制备这种化合物的过程，包括它们的制药组合物，以及与其他抗HCV药物的复合物。
• Pteridines useful as HCV inhibitors and methods for the preparation thereof
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：US09290502B2

  公开（公告）日：2016-03-22

  The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

  本发明涉及使用黄素类物质作为HCV复制抑制剂，以及它们在旨在治疗或对抗HCV感染的药物组合物中的使用。此外，本发明涉及化合物本身及其作为药物的使用。本发明还涉及制备这种化合物的过程，包括它们的制药组合物以及与其他抗HCV剂的复合物。
• Transition-metal-free regioselective hydroamination of styrenes with amino-heteroarenes
  作者：Priyanka Meena、Ayushee、Monika Patel、Akhilesh K. Verma

  DOI：10.1039/d2cc02781j

  日期：——

  The base-mediated anti-Markovnikov hydroamination of functionally varied styrenes with amino-substituted pyridine, quinoline, pyrimidine, pyrazine, and phenanthridine with excellent regioselectivity has been described. Double hydroamination was observed chemoselectively on the secondary amine, leaving the primary amine intact. Experimental evidence suggests that the proposed reaction involves the nucleophilic

  已经描述了具有优异区域选择性的功能不同的苯乙烯与氨基取代的吡啶、喹啉、嘧啶、吡嗪和菲啶的碱介导的抗马尔科夫尼科夫加氢胺化。在仲胺上化学选择性地观察到双氢化胺化，而使伯胺保持完整。实验证据表明，所提出的反应涉及通过单电子转移将氨基吡啶基亲核加成到乙烯基芳烃上。